A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

If an investor was to purchase shares of AZN stock at the current price level of $70.69/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Each stock is assigned ... likelihood its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. AstraZeneca plc, headquartered ...

Absci Corporation’s ABSI share price has surged by 17.57%, which has investors questioning if this is right time to sell.